Cybin (HELP) Cash & Equivalents (2021 - 2025)
Cybin (HELP) posted quarterly Cash & Equivalents of $195.1 million for Q4 2025, up 100.0% year-on-year from $97.6 million in Q4 2024, and up 132.98% on a QoQ basis from $83.8 million in Q3 2025.
Cybin (HELP) Cash & Equivalents (2021 - 2025) Analysis & Trends
Cybin (HELP) has reported Cash & Equivalents for 5 consecutive years, with $195.1 million the latest figure, recorded in Q4 2025.
- Quarterly Cash & Equivalents rose 100.0% year-over-year to $195.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $195.1 million (up 100.0% YoY) and the FY2024 annual result came in at $155.1 million, changed N/A from the prior year.
- Cash & Equivalents grew to $195.1 million in Q4 2025 per HELP's latest filing, from $83.8 million in the prior quarter.
- Over the last five years, Cash & Equivalents for HELP reached as high as $195.1 million in Q4 2025 and fell as low as $7.0 million in Q2 2023.
- A 5-year average of $68.9 million and a median of $50.5 million in 2021 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2022 — Cash & Equivalents sank 67.12% — and 2024, when it soared 1825.32%.
- Year by year, Cash & Equivalents stood at $50.4 million in 2021, then plunged by 67.12% to $16.6 million in 2022, then jumped by 72.73% to $28.6 million in 2023, then soared by 240.58% to $97.6 million in 2024, then jumped by 100.0% to $195.1 million in 2025.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $195.1 million, $83.8 million, and $97.6 million for Q4 2025, Q3 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 82.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.49 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.96 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 3.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 440.94 Mn |
| 10 | Cybin | 28.04 Mn | 28.04 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 195.13 Mn |
| Sep 30, 2025 | 83.75 Mn |
| Dec 31, 2024 | 97.56 Mn |
| Sep 30, 2024 | 113.12 Mn |
| Jun 30, 2024 | 134.00 Mn |
| Mar 31, 2024 | 155.10 Mn |
| Dec 31, 2023 | 28.65 Mn |
| Sep 30, 2023 | 13.51 Mn |
| Jun 30, 2023 | 6.96 Mn |
| Feb 28, 2023 | 30.15 Mn |
| Dec 31, 2022 | 16.58 Mn |
| Sep 30, 2022 | 22.95 Mn |
| Dec 31, 2021 | 50.44 Mn |
| Sep 30, 2021 | 59.72 Mn |
| Jun 30, 2021 | 44.81 Mn |
| Mar 31, 2021 | 50.59 Mn |